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Abstract
Background: WNV-associated encephalitis (WNVE) is characterized by increased production of pro-inflammatory
mediators, glial cells activation and eventual loss of neurons. WNV infection of neurons is rapidly progressive and
destructive whereas infection of non-neuronal brain cells is limited. However, the role of neurons and pathological
consequences of pro-inflammatory cytokines released as a result of WNV infection is unclear. Therefore, the
objective of this study was to examine the role of key cytokines secreted by WNV-infected neurons in mediating
neuroinflammatory markers and neuronal death.
Methods: A transformed human neuroblastoma cell line, SK-N-SH, was infected with WNV at multiplicity of
infection (MOI)-1 and -5, and WNV replication kinetics and expression profile of key pro-inflammatory cytokines
were analyzed by plaque assay, qRT-PCR, and ELISA. Cell death was measured in SK-N-SH cell line in the presence
and absence of neutralizing antibodies against key pro-inflammatory cytokines using cell viability assay, TUNEL and
flow cytometry. Further, naïve primary astrocytes were treated with UV-inactivated supernatant from mock- and
WNV-infected SK-N-SH cell line and the activation of astrocytes was measured using flow cytometry and ELISA.
Results: WNV-infected SK-N-SH cells induced the expression of IL-1b, -6, -8, and TNF-a in a dose- and time-
dependent manner, which coincided with increase in virus-induced cell death. Treatment of cells with anti-IL-1b or
-TNF-a resulted in significant reduction of the neurotoxic effects of WNV. Furthermore treatment of naïve
astrocytes with UV-inactivated supernatant from WNV-infected SK-N-SH cell line increased expression of glial
fibrillary acidic protein and key inflammatory cytokines.
Conclusion: Our results for the first time suggest that neurons are one of the potential sources of pro-
inflammatory cytokines in WNV-infected brain and these neuron-derived cytokines contribute to WNV-induced
neurotoxicity. Moreover, cytokines released from neurons also mediate the activation of astrocytes. Our data define
specific role(s) of WNV-induced pro-inflammatory cytokines and provide a framework for the development of anti-
inflammatory drugs as much-needed therapeutic interventions to limit symptoms associated with WNVE.
Background
West Nile virus (WNV), a mosquito-borne flavivirus
that causes lethal encephalitis has emerged as a signifi-
cant cause of viral encephalitis in the United States [1].
Since its introduction to North America in 1999, out-
breaks of WNV fever and encephalitis have occurred in
regions throughout the United States [1]. The fatality
rate is approximately 10% for hospitalized encephalitic
cases with increased risk in patients with compromised
immune systems, older age and having underlying con-
ditions such as diabetes mellitus [2]. Currently there are
no therapeutic agents or vaccines approved for use
against WNV infection in humans. Following peripheral
infection, WNV replication is first thought to occur in
skin Langerhans dendritic cells. These cells migrate to
and seed draining lymph nodes, resulting in primary vir-
emia [3]. By the end of the first week after infection, the
virus is largely cleared from the peripheral organs, but
* Correspondence: nerurkar@pbrc.hawaii.edu
Retrovirology Research Laboratory, Department of Tropical Medicine, Medical
Microbiology and Pharmacology, John A. Burns School of Medicine,
University of Hawaii at Manoa, 651 Ilalo Street, BSB 325AA, Honolulu, Hawaii
96813, USA
Kumar et al. Journal of Neuroinflammation 2010, 7:73
http://www.jneuroinflammation.com/content/7/1/73
JOURNAL OF 
NEUROINFLAMMATION
© 2010 Kumar et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.in a subset of patients the virus enters the brain and
causes a spectrum of neurological sequeale.
Major hallmarks of WNV neuropathogenesis are neu-
roinflammation followed by neuronal death and disrup-
tion of the blood-brain barrier (BBB) [4,5]. Activation of
glial cells (microglia and astrocytes) together with neu-
ronal death are considered as key pathogenic features of
WNV neuropathogenesis [6,7]. Neuronal death in WNV
infection is a complex process and involves activation of
caspase3/9 dependent apoptosis via both, extrinsic as
well as the intrinsic pathways [8-10]. The mechanism(s)
by which WNV induces neurological sequeale are not
fully understood but it is proposed that apoptotic neuro-
nal death can be a result of both, direct virus infection
or bystander injury caused by cytotoxic factors released
by non-neuronal cells [11].
Though induction of neuroinflammation is an active
defense reaction against insults including virus infections
such as HIV, herpes simplex virus (HSV), Japanese ence-
phalitis virus (JEV) and WNV,i ti sa l s or e c o g n i z e da sa
major contributor of neuropathogenesis [12-16]. Acti-
vated central nervous system (CNS) cells and/or infiltrat-
ing immune cells produce several proinflammatory and
neurotoxic mediators including cytokines, chemokines,
arachidonic acid and its metabolites [13,17]. Cytokines
such as interleukin (IL)-1b and tumor necrosis factor
(TNF)-a have been reported as potent inducers of neuro-
nal injury in several neurodegenerative diseases such as
cerebral ischemia, spinal cord injury, multiple sclerosis
and viral infections including HIV-associated dementia
(HID), JE and influenza [14,16,18,19]. The receptors of
cytokines are expressed constitutively throughout the
CNS, including neurons [15], thereby rendering them
sensitive to these cytokines even at very low level [20].
The response of WNV infection in the brain is charac-
terized with massive inflammatory events including pro-
duction of cytokines such as IL-1b,- 6a n dT N F - a,a n d
chemokines [4,11,21,22]. Studies aimed at understanding
the role of innate immune response in WNV-infected
brain have so far largely focused on chemokines. The
role of the chemokines such as MCP-5 (or CCL12),
IP-10 (or CXCL10), MIG (or CXCL9) have been estab-
lished in recruitment of virus-specific T-cells and virus
clearance [21,23]. However the role of pro-inflammatory
c y t o k i n e ss u c ha sI L - 1 b and TNF-a in neuropathogen-
esis following WNV infection remains obscure. Few stu-
dies have recently characterized the role of TNF-a in
WNV infection in a mouse model, but the data remain
controversial [24-26]. Although microglia and astrocytes
are classically believed to serve as the predominant
source of these cytokines in the CNS, neurons can
highly express these cytokines in the setting of disease,
including Alzheimer’sd i s e a s e( A D ) ,s p i n a lc o r di n j u r y ,
stroke, and sciatic nerve injury [27-29]. Since neurons
are the prime target for WNV replication, it seems likely
that they may act as a central processor of inflammation
by releasing pro-inflammatory molecules. These pro-
inflammatory molecules may further activate down-
stream apoptotic signaling pathway(s) in neurons
ultimately resulting in neuronal death and/or activate
glial cells, which can further exacerbate neuroinflam-
mation. Herein, we directly evaluate the ability of
WNV-infected neurons to produce key proinflammatory
cytokines and their role in mediating neuroinflammatory
markers and neuronal death.
Materials and methods
Cells, virus and plaque assay
A transformed human neuroblastoma cell line, SK-N-SH,
purchased from the American Tissue Culture Collection
(ATCC, Manassas, VA) and primary human brain corti-
cal astrocytes (HBCA) cells purchased from ACBRI
(Kirkland, WA) at passage 2, were propagated as
described previously [30,31]. All experiments were con-
ducted with cells between passages 6 to 9. For infection,
SK-N-SH cell line grown to 90% confluency in 6-well
plates (6 × 10
5 cells/well) were infected with WNV
(NY99) at the multiplicity of infection (MOI)-1 or -5 as
described previously [30,32]. Briefly, the virus was
adsorbed for 1 h at 37°C. After incubation, unadsorbed
virus was removed by washing twice with PBS and cells
were further incubated with fresh media. The superna-
tant and cells were collected at 2 h and from days 1 to 4.
Production of infectious virus in the supernatant was
determined by plaque assay using Vero cells as described
previously [30,32].
Quantitative real time reverse transcriptase-PCR (qRT-
PCR) analysis
cDNA synthesized from RNA extracted from human
neuroblastoma cell line, SK-N-SH, and HBCA cells
under different conditions were used for qRT-PCR as
described previously [30-33]. Primer sequences and
annealing temperatures employed for amplification of
pro-inflammatory cytokines are described in Table 1.
Treatment of WNV-infected human neuroblastoma cell
line, SK-N-SH, with specific neutralizing antibodies against
pro-inflammatory cytokines and cytotoxicity assay
SK-N-SH cells seeded on cover slips in 24-well plates
(6 × 10
4 cells/well) or in 96-well plates (2 × 10
4 cells/
well) were infected with WNV at MOI-1. After infec-
tion, the cells were replenished with either fresh media
only or media containing specific neutralizing antibodies
against IL-1b (Sigma), -6, -8 or TNF-a (R&D Systems).
The concentration of IL and TNF-a antibodies
employed in this study was 4 and 10 μg/mL, respec-
tively. Cell viability was assessed at days 1 to 3 after
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Proliferation Assay (Promega) as described previously
[30]. At day 2, cells were also fixed with 4% PFA for 10
min at room temperature (RT) for TUNEL assay.
Treatment of naïve HBCA cells with WNV-infected UV-
inactivated supernatant from human neuroblastoma cell
line, SK-N-SH, and cytotoxicity assay
Supernatant derived from WNV-infected SK-N-SH cells
cultured for 48 h was UV-inactivated in order to inacti-
vate WNV and virus inactivation was confirmed by pla-
que assay as described previously [32]. HBCA cells grown
in 24-well plates (6 × 10
4 cells/well) were incubated for 6
hw i t h5 0 0μL of the above UV-inactivated supernatant
from mock- or WNV (MOI-1) -infected SK-N-SH cells.
After 6 h of treatment with UV-inactivated supernatant,
HBCA cells were washed once with 1× PBS, followed by
incubation at 37°C with HBCA culture media. After 24 h
and 48 h, HBCA cells were harvested and supernatant
was collected and stored for later use. Similarly,
HBCA cells grown in 96-well plates were treated as
above and cell viability assay was conducted as described
previously [30].
ELISA
The levels of IL-1b, -6, -8 and TNF-a were measured in
the cell supernatant by ELISA, using the Quantakine
kits (R&D Systems). The tests were conducted according
to the manufacturer’s instructions and the plates were
analyzed using a Victor 3 microtiter reader equipped
with Workout 1.5 software as described previously [31].
TUNEL assay
Apoptosis in SK-N-SH cells treated as described above
was measured using the TUNEL assay. TUNEL assay
was conducted using the In Situ Cell Death Detection
kit, TMR red (Roche Diagnostics, Indianapolis, IN) in
accordance with the manufacturer’s protocol. In brief,
PFA fixed cells were permeabilized for 2 min in 0.1%
Triton X-100/sodium citrate at 4°C. Cells were further
incubated with 50 μL of TUNEL reaction mixture con-
taining TdT (Terminal Deoxynucleotidyltransferase) in a
humidified chamber at 37°C, washed twice with 1× PBS
and then counterstained with bisbenzidine (1 ng/mL)
before mounting onto a slide with Vectashield mounting
medium (Vector Laboratories, Burlingame, CA). For
negative control, cells were processed using a reaction
mixture that did not contain TdT. For positive control,
cells were incubated with DNase I (3 U/mL) for 10 min
to induce DNA strand breaks. Apoptosis was detected
by fluorescence microscopy on a Zeiss Confocal Pascal
equipped with a Zeiss Axiovert 200 microscope,
equipped with appropriate fluorescence filters and
objectives. The TUNEL-positive cells for each group
was obtained by counting total 2,500 to 3,500 cells from
nine different fields for each coverslip from three inde-
pendent experiments.
Flow Cytometry
Flow cytometry was conducted using the In Situ Cell
Death Detection kit, Fluorescein (Roche Diagnostics,
Indianapolis, IN) to detect TUNEL-positive SK-N-SH
cells that had been treated as described above. SK-N-SH
cells were trypsinized, washed twice with cold PBS
before fixing in 4% PFA solution. Cells were further
incubated with 50 μL of TUNEL reaction mixture con-
taining TdT (Terminal Deoxynucleotidyltransferase) in a
humidified chamber at 37°C. Cells were washed and
resuspended in 200 μL of PBS, and flow cytometry was
conducted using the FACSAria (BD Biosciences).
In another set of experiment, HBCA cells treated with
UV-inactivated supernatant from SK-N-SH cells as
described previously were trypsinized at 48 h and
washed twice with cold PBS before fixing in 4% PFA
solution. Cells were then incubated first with monoclo-
nal human anti-glial fibrillary acidic protein (GFAP)
antibody (1:1000, DakoCytomation) at 4°C for 1 h and
then with Alexa Fluor 546 conjugated goat anti-rabbit
Table 1 Primer sequences used for qRT-PCR
Gene Primer Sequence (5’-3’) Amplicon
[GenBank
No.]
(bp) Tm (°C)
IL-1b
[GenBank:
NM_000576]
Forward AGCACCTTCTTTCCCTTCATC 86 56
Reverse GGACCAGACATCACCAAGC
IL-6
[GenBank:
NM_000600]
Forward CCAGGAGCCCAGCTATGAAC 84 57
Reverse CCCAGGGAGAAGGCAACTG
IL-8
[GenBank:
NM_000584]
Forward GAACTGAGAGTGATTGAGAGTGGA 91 55
Reverse CTCTTCAAAAACTTCTCCACAACC
TNF-a
[GenBank:
NM_000594]
Forward CCTGCCCCAATCCCTTTATT 81 55
Reverse CCCTAAGCCCCCAATTCTCT
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C in dark. Cells were washed and resuspended in 200
μL of PBS, and flow cytometry was conducted as
described above.
Statistical analysis
Data are reported as mean ± standard deviation (SD) of
at least three independent experiments performed in
duplicate. Unpaired student t-test using GraphPad Prism
5.0 (GraphPad software) was used to calculate p values.
Differences of P < 0.05 were considered significant.
Results
WNV can infect and replicate in human neuroblastoma
cell line, SK-N-SH
We examined the susceptibility of SK-N-SH cells to
WNV infection and characterized the kinetics of virus
replication. Replication kinetics was analyzed by measur-
ing WNV titer in the culture supernatants of infected
cells collected at 2 h and from days 1 to 4 after infec-
tion. Plaque assay data demonstrated a robust increase
in virion production from days 1 to 4 after infection
with WNV at both, MOI-1 and -5 (Figure 1A). A seven-
log10 PFU/mL increase in virus titer was observed at day
1 after infection in MOI-1 and -5 infected cells. At day
3, virus titer reached its peak of nine-log10 PFU/mL in
MOI-5 infected cells, which declined slightly at day 4.
In MOI-1 infected cells, a sharp increase in the virus
titer (two-log10 PFU/mL) was observed on days 2 and 3
after infection, which remained elevated till day 4 after
infection. The kinetics of virus replication was similar to
previously observed WNV infection of primary neurons
and cell lines such as LAN-2 [11,22,34].
WNV induces apoptosis of human neuroblastoma cell
line, SK-N-SH
WNV is known to induce neuronal cell death. Therefore,
we examined the effect of WNV infection on cell viability
of SK-N-SH cells. Cytotoxicity of WNV-infected SK-N-
SH cells at different MOIs demonstrated an increase in
the cell death in a dose- and time-dependent manner. As
illustrated in Figure 1B, at day 1 there was no change in
the cell viability of WNV-infected cells when compared
to the control cells. However, at day 2 after infection
with WNV at MOI-0.1, -0.5, -1, and -5, the cell toxicity
increased to 14%, 25%, 26%, and 49% respectively, which
continued to increase in a dose-dependent manner till
day 3 after infection. This drastic increase in the cell
death correlates well with the sharp increase in virus
titers at the same time points (Figure 1A), further con-
firming the effect of WNV in inducing cell death.
To further determine that WNV-induced cell death is
by apoptosis, we conducted TUNEL assay to detect
DNA fragmentation, a hallmark of apoptosis. As shown
in Figure 1C, very few TUNEL-positive cells were
detected in mock-infected cells whereas at day 2 after
WNV infection approximately 25% cells were TUNEL
positive. Consistent with previously published studies,
our data provides further support that apoptosis is
the main mechanism by which WNV triggers neurotoxi-
city [9,11,34].
WNV induces expression of multiple pro-inflammatory
cytokines in human neuroblastome cell line, SK-N-SH
Pro-inflammatory cytokines such as IL-1b and TNF-a
play an important role in mediating neuronal death and
neuroinflammation in various neurodegenerative dis-
eases [14,17-19,35]. Therefore, we investigated the
effect of WNV infection on the expression of key pro-
inflammatory cytokines such as IL-1b,- 6 ,- 8 ,- 1 8a n d
TNF-a in human neuroblastoma cell line SK-N-SH at
both mRNA and protein levels. At day 1 after infection
no significant increase was observed in the mRNA
expression of any pro-inflammatory cytokines in both
MOI-1 and -5 infected cells (Figure 2A). While IL-18
expression did not change at any time point (data not
shown), a robust up-regulation was detected in the
expressions of IL-1b, -6, -8, and TNF-a at days 2 and 3
after infection with both MOI-1 and -5 of WNV, which
coincided with increase in cell toxicity following WNV
infection (Figure 1B). Moreover, in accordance with the
cell toxicity data, induction in these cytokine expressions
was more in MOI-5 as compared to MOI-1 infected
cells. As depicted in Figure 2A, mRNA expressions of
IL-1b, -6 and TNF-a increased gradually from days 2 to
3 in both MOI-1- and -5-infected cells. Maximum
increase in the expression of IL-1b,- 6a n dT N F - a
mRNA was in the range of 60- to 120-fold, at day 3 in
MOI-5 infected cells. Maximum increase in the expres-
sion of IL-8, 84-fold, was detected at day 2 in MOI-5
infected cells, which decreased to 48-fold at day 3,
whereas IL-8 expression remained approximately same
at both days 2 and 3 in MOI-1-infected cells.
As these pro-inflammatory cytokines are secreted pro-
teins, their release in the culture media of mock- and
WNV (MOI-1) -infected SK-N-SH cells was detected
using ELISA. In controls, basal levels of IL-1b,- 6a n d
TNF-a in cell culture media were very low. On the
other hand, significant amounts of soluble IL-1b, -6 and
TNF-a were detected in supernatant from infected cells
at day 2 and 3 after infection (p < 0.05, Figure 2B). In
accordance with mRNA data, release of these cytokines
was increased at day 2 and peaked at day 3 after infec-
tion. In contrast, basal level of IL-8 was relatively high,
but it also increased substantially after WNV infection,
at days 2 and 3 after infection (p < 0.001, Figure 2B).
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neuroblastoma cell line, SK-N-SH, cell death
To characterize the potential relationship between WNV-
induced neuronal death and increased expression of IL-1b,
-6, -8, and TNF-a, SK-N-SH cells were infected with
WNV at MOI-1, in presence or absence of IL-1b, -6-, -8-,
or TNF-a-neutralizing antibodies. Incubation of cells with
IL-1b-neutralizing antibody resulted in significant (p <
0.05) reduction of the neurotoxic effects of WNV infec-
tion. The cell toxicity decreased by 50% at day 2 after
infection in IL-1b-neutralizing antibody treated WNV-
infected SK-N-SH cells when compared to WNV-infected
SK-N-SH cells. Neutralization of TNF-a also significantly
(p < 0.05) rescued WNV-induced cell death at day 2 after
infection ( < 50% when compared to WNV-infected cells).
On the other hand, protection of cells in the presence
of anti-IL-6 and -8 for virus-induced cell death was not
significant (Figure 3A).
The specificity of the neuroprotective role elicited by
IL-1b and TNF-a neutralizing antibodies was further
confirmed by TUNEL assay. As depicted in Figure 3B,
TUNEL-positive cells were abundant in WNV-infected
cells at day 2 after infection, which reduced significantly
( p< 0 . 0 5 )i nt h ep r e s e n c eo fa n t i - I L - 1 b or -TNF-a.A s
demonstrated in Figure 3C, the number of TUNEL-posi-
tive cells in WNV-infected SK-N-SH cells treated with
anti-IL-1b or TNF-a at day 2 were significantly (p <
0.05) lower, 26 and 28 cells per field, respectively, as
compared to WNV-infected cells, 68 cells per field.
Consistent with the cell toxicity data, the results of
TUNEL assay confirmed that the neutralization of IL-1b
and TNF-a protected SK-N-SH cells against WNV-
induced apoptosis. The specificity of neutralizing antibo-
dies in protecting cell death was further confirmed
using flow cytometry. Flow cytometry data demonstrated
that WNV-induced SK-N-SH cells apoptosis (25.8%)
was significantly suppressed in the presence of neutraliz-
ing antibodies against IL-1b (12.3%) and TNF-a (13.5%)
(p < 0.05, Figure 4) at day 2 after infection.
Pro-inflammatory mediators released from WNV-infected
human neuroblastoma cell line, SK-N-SH, activate naïve
HBCA cells
Human astrocytes produce a wide variety of chemokines
and cytokines upon exposure to pro-inflammatory stimuli.
Activation of astrocytes is also one of the major hallmarks
of WNV infection [11,22,34]. Therefore, we next investi-
gated the contribution of the pro-inflammatory cytokines
Figure 1 WNV can infect and induce apoptosis in human neuroblastoma cell line, SK-N-SH. (A) WNV titers in culture supernatant from SK-N-SH
cell line collected at 2 h and from days 1 to 4 after infection were determined by plaque assay using Vero cells. Viral titers are expressed as plaque
forming units (PFU)/mL of supernatant. Data are expressed as mean ± SD for two independent experiments conducted in duplicate. (B) Cell toxicity of
SK-N-SH cells from days 1 to 3 after WNV infection was assessed by cell proliferation assay and percentage cell toxicity was calculated by comparing to
mock-infected cells at corresponding time points. Data are expressed as mean ± SD for three independent experiments conducted in triplicate. (C)
Mock (i and ii), and WNV (MOI-1)-infected SK-N-SH cells (iii and iv) were fixed at day 2 after infection and TUNEL assay was conducted (red; i and iii).
Cells were counterstained with DAPI to label nucleus. TUNEL plus DAPI images (ii and iv) indicate that number of cells in each field were similar. DNase
I-treated cells were used as positive control (v). The images depict representative results of three independent experiments.
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cDNA templates from mock- and WNV-infected SK-N-SH cells from days 1 to 3 after infection were used to determine the fold-change of IL-1b,
-6, -8, and TNF-a by qRT-PCR. Changes in the levels of pro-inflammatory cytokines were first normalized to the GAPDH gene and the fold-
change in infected cells as compared to corresponding controls was calculated. Data represents mean ± SD of five independent experiments
conducted in duplicate. (B) Levels of IL-1b, -6, -8, and TNF-a in culture supernatants were determined by ELISA. WNV (MOI-1) infection
significantly increased the production of pro-inflammatory cytokines. The data expressed are the mean concentration (pg/ml) ± SD of the
amount of IL-1b, -6, -8 or TNF-a, secreted in the supernatant and is representative of three independent experiments. *p < 0.05. **p < 0.001.
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neuroinflammatory markers, as assessed by activation of
astrocytes and release of various pro-inflammatory
cytokines.
As depicted in Figure 5A, the intensity of GFAP fluores-
cence increased significantly (p < 0.05) in HBCA cells
treated with UV-inactivated infected SK-N-SH cells super-
natant (68.1%) as compared to those treated with UV-
inactivated mock-infected SK-N-SH cells supernatant
(46.9%) at 48 h after treatment. Figure 5B depicts sharp
increase in the production of IL-1b, -8, -6, and TNF-a
within 24 h of treatment of naïve HBCA cells with
UV-inactivated supernatant from WNV-infected SK-N-SH
cells when normalized with those treated with UV-
inactivated supernatant from mock-infected SK-N-SH
cells. We then analyzed the amount of these cytokines
released in naïve HBCA cells treated with UV-inactivated
supernatant derived from SK-N-SH cells and compared it
to the kinetics of cytokine production by HBCA cells
directly infected with WNV (MOI-1). In accordance with
the mRNA data, the release of IL-1b,- 6 ,- 8a n dT N F - a
from HBCA cells treated with UV-inactivated supernatant
derived from WNV-infected SK-N-SH cells was compara-
tively much higher than those treated with mock-infected
SK-N-SH cells supernatant after 24 and 48 h as measured
by ELISA (p < 0.05, Figure 6). It was interesting to note
that all cytokines produced by WNV-infected HBCA cells
were not significantly high at 24 hr after infection and a
sharp increase occurred only at 48 h after infection, (Fig-
ure 6) which coincided with the peak in virus replication
[31]. Furthermore, infection of astrocytes with only UV-
inactivated WNV (MOI-1) did not induce the expression
of aforementioned cytokines at any time point (Figure 6)
thus ruling out the contribution of UV-inactivated WNV
in inducing this effect on HBCA cells. These data collec-
tively demonstrate that the supernatant derived from
WNV-infected SK-N-SH cell line is capable of activating
HBCA cells.
Figure 3 Neutralization of IL-1b and TNF-a protects cell death of human neuroblastoma cell line, SK-N-SH. (A) WNV (MOI-1)- infected
SK-N-SH cells were treated with neutralizing antibodies against IL-1b-, -6-, -8-, or TNF-a and cell toxicity was assessed by cell proliferation assay.
Percentage cell toxicity was calculated by comparing to control cells. While neutralization of IL-8 and IL-6 did not result in significant reduction
in WNV-induced cell death, it was significantly attenuated in the presence of anti-IL1b or -TNF-a at day 2 after infection. Data are expressed as
mean ± SD from three independent experiments conducted in triplicates. (B) WNV (MOI-1)-infected SK-N-SH cells were treated with anti-IL-1b or
-TNF-a and assessed for apoptosis at day 2 after infection. Abundant TUNEL-positive cells (red, i) co-localized with DAPI (blue; ii) were observed
in WNV-infected cells. In contrast, apoptosis induced by WNV was significantly attenuated in the presence of anti-IL-1b (iii) and anti-TNF-a (v).
The images depicted are representative results of three independent experiments. (C) Quantitative representation of TUNEL-positive cells in each
group from three independent cover slips from three independent experiments. Quantitative analysis indicated that neutralization of IL-1b and
TNF-a reduced the number of TUNEL positive cells to less than half compared to WNV-infected cells. *p < 0.05.
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Page 7 of 14Figure 4 Protection of human neuroblastoma cell line, SK-N-SH, toxicity as assayed by FACS analysis. FACS analysis of TUNEL-positive
cells in (A) mock and (B) WNV (MOI-1)-infected SK-N-SH cells treated with (C) anti-IL-1b or (D) anti-TNF-a at day 2 after infection. (E) DNase I-
treated cells were used as positive control. The images depicted in panels A to E are representative data of three independent experiments. (F)
TUNEL-positive cells reduced significantly in the presence of neutralizing antibodies against IL-1b and TNF-a. Data in panel F are expressed as
mean ± SD for three independent experiments conducted in duplicate. **p < 0.001 as compared to mock, *p < 0.05 compared to
corresponding infected cells.
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WNV-infection of brain leads to induction of several cyto-
kines and chemokines, which promote WNV-CNS inva-
sion and trigger neuroinflammation [5,11,23]. As a
consequence, leukocytes are recruited to the CNS, which
are critical for virus clearance [36,37]. However what
remains unclear is the extent to which this inflammation
contributes to disease pathology and poor prognosis
[38,39]. The relative contribution of resident CNS cells,
specifically neurons as a mediator of this inflammation is
unknown. Here we demonstrate that (i) WNV-infected
SK-N-SH cells are one of the potential sources of inflam-
matory cytokines, (ii) WNV-induced pro-inflammatory
cytokines contribute to SK-N-SH cell death and glial cells
activation, and (iii) WNV-induced SK-N-SH cell death can
be protected in the presence of neutralizing antibodies
against IL-1b and TNF-a.
Neurons as one of the potential sources of pro-
inflammatory cytokines in WNV-infected brain
Increased production of cytokines in the brain is a com-
mon event observed during infection with neurotropic
viruses such as herpesviruses, JC virus, retroviruses (HIV
and HTLV-1), poliovirus, rabies virus and arboviruses
(JE, St. Louis encephalitis) [12-14,16,40]. Inflammation in
the brain is usually characterized by infiltration of
Figure 5 UV-inactivated supernatant from WNV-infected human neuroblastoma cell line, SK-N-SH, activates astrocytes and induces
expression of pro-inflammatory cytokines. (A) FACS analysis of GFAP expression in naïve HBCA cells treated with UV-inactivated supernatant
derived from mock- and WNV (MOI-1)-infected SK-N-SH cells at 48 h after treatment is shown as overlapped histograms with the mean
fluorescence intensity (MFI) in arbitrary units at the right. The MFI of GFAP increased significantly in HBCA cells treated with UV-inactivated
supernatant from infected SK-N-SH cells (*p < 0.05). Data are representative of three independent experiments. (B) cDNA templates synthesized
from RNA extracted from HBCA cells at 6, 24 and 48 h after treatment with UV-inactivated supernatant from SK-N-SH cells were used to
determine the fold-change of IL-1b, -6, -8, and TNF-a by qRT-PCR. Changes in the levels of pro-inflammatory cytokines were first normalized to
the GAPDH gene and then the fold-change in infected supernatant treated cells as compared to corresponding controls was calculated. Data
represents mean ± SD of five independent experiments conducted in duplicate.
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butors of these cytokines [13,41,42]. We and others have
recently demonstrated in vitro increased production of
cytokines and matrix metalloproteinases (MMPs) by
WNV-infected astrocytes and microglia [11,22,31]. Since
neurons are the prime target of WNV infection, we
examined the ability of WNV-infected human neurobla-
tostoma cell line, SK-N-SH, in producing key cytokines.
In this report for the first time we demonstrate that neu-
rons also respond to WNV infection by up-regulating
cytokines production. The sharp increase of key pro-
inflammatory cytokines such as IL-1b,- 6 ,- 8a n dT N F - a
at day 2 after infection as determined by qRT-PCR and
ELISA is significant and coincides with peak virus repli-
cation in SK-N-SH cells suggesting that active virus repli-
cation in these cells is a main determinant of cytokines
up-regulation (Figure 2). Neurons secrete several cyto-
kines under various brain insults [43]. In the normal
intact CNS, neurons are the only cell type known to pro-
duce low levels of TNF-a [44,45]. IL-6 mRNA has been
described within hippocampal and cerebellar neurons of
the adult mammalian brain [46,47]. Treatment of neu-
rons with S100B induces the expression of IL-1b and -6
[41,48]. Neurons highly express cytokines such as IL-6,
-1b,a n dT N F - a in neurodegenerative diseases, including
AD, spinal cord injury, stroke, and sciatic nerve injury
[27-29,49]. In diseases like AD and JE, increased cytokine
production by dying neurons is the main determinant of
cytotoxicity [41,50,51]. It is important to note that in
HIV, another neurotropic virus, which does not infect
neurons, the main source of cytokine production are glial
cells [14,16,52]. However unlike HIV, WNV infection of
n e u r o n si sr o b u s t ,t h e r e f o r ebased on our data, it seems
likely that they may be one of the main sources of cyto-
kines in WNV-associated neuroinflammation. Though,
our data does not rule out the possibility of cytokine pro-
duction by glial cells and infiltrating immune cells in
WNV-infected brain. Neurons have not been implicated
as a source of IL-18 in various brain insults, therefore, no
change in the expression of IL-18 (data not shown) is not
surprising. Moreover, literature suggests glial cells as the
main source of IL-18 upon various stimuli [53], including
infection with JEV [16] and WNV (Verma et. al., unpub-
lished data).
Neurons-derived cytokines contribute to neuronal death
by apoptosis
Cytokines and their respective receptors/ligands are cru-
cial components comprising communication network in
brain and immune system [18,54]. Considerable evi-
dence indicates that when over produced, these cyto-
kines mediate diverse range of neurodegenerative
functions including disruption of the BBB, chemoattrac-
tion of peripheral immune cells and neuronal damage
Figure 6 UV-inactivated supernatant from WNV-infected human
neuroblastoma cell line, SK-N-SH, induce the secretion of pro-
inflammatory cytokines from astrocytes. Naïve HBCA cells were
either mock-treated or infected with UV-inactivated WNV or WNV at
MOI-1 or treated with UV-inactivated supernatant derived from
mock- and WNV (MOI-1)-infected SK-N-SH cells, and levels of IL-1b, -6,
-8, and TNF-a in treated or infected HBCA culture supernatants were
determined by ELISA. Supernatant derived from UV-inactivated
mock- and WNV-infected SK-N-SH cells significantly increased the
production of pro-inflammatory cytokines within 24 h after
treatment. While WNV infection per se increased the production of
these cytokines only after 48 h. Furthermore, infection of astrocytes
with only UV-inactivated WNV did not induce the expression of
aforementioned cytokines at any time point. The data expressed are
the mean concentration (pg/ml) ± SD of the amount of IL-1b, -6, -8
or TNF-a, secreted in the supernatant and is representative of three
independent experiments. *p < 0.05. **p < 0.001.
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TNF-a have been proposed as potent mediators of neu-
ronal death in several neurodegenerative diseases like
AD, traumatic brain injury, epilepsy, Parkinson’s disease,
stroke, HIV and JE [12-14,16]. Based on our observation
of direct correlation of cytokine production from WNV-
infected SK-N-SH cells with cell toxicity (Figures 1 and
2), we next investigated the effect of these cytokines by
using specific neutralizing antibodies against these cyto-
kines. Protection of cell death as well as reduction of
TUNEL positive cells in the presence of anti-IL-1b and
anti-TNF-a strongly suggests that WNV-induced pro-
inflammatory cytokines are one of the main factors driv-
ing cell death (Figures 3 and 4). Recent studies on JEV
also support the role of TNF-a, where increased expres-
sion of TNF-a receptor in neurons directly results in
the initiation of death cascade via TRADD [51]. TNF-a
also contributes to neuronal death in brain ischemia
[55,56]. Both TNF-a and IL-1b sensitizes neurons for
tat-induced apoptosis in HAD [14]. Moreover, in vivo
studies in animal models of experimental autoimmune
encephalomyelitis (EAE) have demonstrated that block-
ing of TNF-a by neutralizing antibodies, or drugs, ame-
liorates the disease [57-59]. Central or peripheral
administration of IL-1b dramatically increases neuronal
death following acute brain injury [60,61]. Studies also
support that IL-1b is the key mediator of caspase-1-
dependent apoptosis of neurons [62]. IL-1b has been
demonstrated to cause bystander damage to JEV-
infected neurons [16]. Therapeutic blockade of IL-1
receptors also conferred significant protection in a mur-
ine model of fatal alphavirus encephalomyelitis [63].
Our results demonstrating no significant change in SK-
N-SH cell death in presence of neutralizing antibodies
to IL-6 and -8 was not surprising, as these cytokines are
not involved in inducing cytotoxicity [42]. Moreover,
production of IL-6 is under the control of IL-1b and its
pathogenic roles include induction of other cytokines
and chemokines [18]. Our data has inherent limitation
wherein we are unable to pinpoint that infected and/or
uninfected SK-N-SH cells were protected from cell
death.
Cytokines secreted by WNV-infected neurons activate
astrocytes
Astrocytes, the major CNS cell type provides structural
support to neurons and become activated in neuroin-
flammatory scenarios and produce pro-inflammatory
cytokines. Signals of astrocyte activation that includes
pro-inflammatory cytokines a n dn i t r i co x i d em a yr e s u l t
from infected or injured glial, infiltrating immune, and/
or endothelial cells or from injured neurons per se
[13,42]. WNV-induced increased production of cyto-
kines [11,22] (Verma et. al., unpublished data) and
MMPs have been demonstrated in astrocytes [31]. Acti-
vation of glial cells has been demonstrated in WNV-
infected brain [6,7,64]. However, since the infection of
astrocytes by WNV in vitro is limited [22,31] and has so
far not been convincingly demonstrated in vivo
[11,64-66], the trigger of glial cells activation might be
produced by non-glial cells. Therefore we hypothesized
that cytokines released from infected neurons might be
one of the initiator of glial cells activation.
Our results as depicted in Figure 5A provide direct
evidence that neurotoxic mediators released from
infected human neuroblastoma cell line SK-N-SH can
activate astrocytes as measured by significant increase in
the expression of GFAP. Increased GFAP expression as
a marker of astrocyte activation has been documented
in various studies [67,68]. The production of inflamma-
tory cytokines is significantly up-regulated in naïve
astrocytes treated with UV-inactivated supernatant from
only infected SK-N-SH cell line, not from naive SK-N-
SH cells (Figures 5B and 6). Since supernatant from
WNV-infected SK-N-SH cell line was UV-inactivated
and UV-inactivated WNV does not induce the expres-
sion of any cytokines upon infection (Figure 6) suggests
that activation of astrocytes is mediated by SK-N-SH
cells-derived inflammatory mediators only and is not the
effect of WNV present in UV-inactivated supernatant.
In addition, when the kinetics of cytokine production by
astrocytes treated with UV-inactivated infected superna-
tant derived from SK-N-SH cell line was compared with
cytokine profile produced by direct infection of astro-
cytes with WNV, we observed that direct WNV infec-
tion induced cytokines only at 48 h after infection. This
could be explained by the fact that WNV infection in
astrocytes peaks at day 2 and coincides with cytokine
production [31]. Whereas, in astrocytes treated with
UV-inactivated infected supernatant from SK-N-SH cells
cytokines were produced at early time point, 24 h after
treatment, and fold-change of cytokine gene expressions
was also significantly higher. This fold-change of cyto-
kine gene expression decreased at 48 h after treatment
which may be due to the short half-life of cytokines in
UV-inactivated infected supernatant [69,70]. The cyto-
kines and chemokines released from injured neurons
have been shown to activate non-neuronal CNS resident
cells [41,51,71-73]. Based on our data, we cannot pin-
point the specific neurotoxic mediator derived from
infected neurons contributing to astrocytes activation.
However, available literature suggests that several factors
including IL-1b and TNF-a are capable of glial cells
activation [41,43,74].
The subsequent consequence of astrocyte activation
and downstream cascade of inflammatory cytokine pro-
duction is the secondary wave of inflammation resulting
in the death of neurons. Activation of glial cells is a key
Kumar et al. Journal of Neuroinflammation 2010, 7:73
http://www.jneuroinflammation.com/content/7/1/73
Page 11 of 14pathogenic feature of WNV-associated meningoence-
phalitis [6,7]. Neurotoxic molecules from WNV-infected
astrocytes have been demonstrated to induce indirect
toxicity in un-infected neurons in vitro [11]. Our recent
data demonstrating the disruption of tight junctions of
the BBB by MMPs released from WNV-infected astro-
cytes further confirms the role of astrocytes in WNV
pathogenesis [31]. These data signify the importance of
astrocyte activation in WNV neuropathogenesis. Simi-
larly, a model proposed by Swarup and colleagues, also
argues that neuronal apoptosis and subsequent microglia
activation in JEV infection results in bystander injury of
un-infected neurons [51]. Further, blocking the down-
stream effects of TNF-a in JEV infection resulted in
abrogation of direct neuronal death as well as bystander
death mediated by activated microglia [51]. Based on
these reports and data reported in this study, we suggest
that in WNV infection also, neurons-mediated activation
of astrocytes may result in several downstream patholo-
gical events such as bystander death of neurons,
increased expression of cell adhesion molecules, chemo-
taxis of activated as well as infected peripheral immune
cells and disruption of the BBB.
Conclusion
In summary, our data demonstrate neurons as an essen-
tial responder to innate immune response to WNV and
one of the potential sources of cytokines in brain. Con-
siderable efforts are currently directed on targeting pro-
inflammatory cytokines as novel therapeutic approach
for the treatment of neurodegenerative diseases [19,43].
In vitro as well as in vivo studies have established that
attenuating the cytokine production in brain directly
correlates to improved disease outcome in virus infec-
tion [14,16,51,52] and in neurological disease models
such as EAE and multiple sclerosis (MS) [13,17]. Broad
spectrum and specific anti-inflammatory drugs such as
IL-1ra and TACE-inhibitors are recommended as
adjunct therapy to control disease progression of various
neurodegenerative diseases such as stroke, cerebral
ischemia, traumatic brain injury and MS [17,19]. Cur-
rently there is no WNV vaccine for humans and once
the virus enters the brain, nothing much can be done.
Therefore, the significance of our studies lies in deli-
neating specific cell types and downstream pathways
associated with cytokine production in WNV-infected
brain, and lay a framework for future in vivo studies
using mouse model to test the ability of anti-IL and
TNF drugs to improve WNV disease outcome.
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